Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evaluation of the MosaiQ™ Platform Chosen as a Top Poster at the AABB 2013 Annual Meeting View HTML
Toggle Summary FDA Licenses Eight New Quotient Reagent Products for Sale in the U.S.
Products are rare antisera blood typing reagents developed and manufactured by Quotient U.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotyping Equivalent products are already approved and commercialized outside of the
View HTML
Toggle Summary Quotient and Ortho Clinical Diagnostics Establish Exclusive Commercial Partnership for MosaiQ(TM) in the Global Patient Testing Market and Donor Testing Markets in the Developing World and Japan View HTML
Toggle Summary Quotient Appoints Dr. Roger Dodd as Senior Scientific Advisor to the Donor Disease Screening Development Team for MosaiQ(TM) View HTML
Toggle Summary Quotient Appoints Heino von Prondzynski to Board of Directors View HTML
Toggle Summary Quotient Appoints Sarah O'Connor to Board of Directors View HTML
Toggle Summary Quotient Awarded Group Purchasing Contract with Premier, Inc. for Blood Bank Reagents
JERSEY, Channel Islands, April 21, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that its U.S. subsidiary, Quotient Biodiagnostics, Inc. ("Quotient Biodiagnostics"), has signed a national group purchasing agreement with Premier,
View HTML
Toggle Summary Quotient Awarded UK's Highest Accolade for Business Success
Leader in the development and manufacture of transfusion diagnostic products awarded prestigious Queen's Award for outstanding achievement in international trade
View HTML
Toggle Summary Quotient Biodiagnostics Conducts Successful Industry Workshop, "The Myth and Mystery of RhD" at 2011 AABB View HTML
Toggle Summary Quotient Biodiagnostics Launches New ALBAcheck® Competency Training Kit and Three New Reagents View HTML